Problems of Social Hygiene, Public Health and History of MedicineProblems of Social Hygiene, Public Health and History of Medicine0869-866X2412-2106Joint-Stock Company Chicot166410.32687/0869-866X-2023-31-2-233-241Научная статьяTHE PREFERENTIAL STRATEGIES OF PROGRAMS OF CERVICAL VIROLOGIC SCREENING (PUBLICATIONS REVIEW)OlkovI. G.GrishinaN. K.N. A. Semashko National Research Institute of Public Health, 105064, Moscow, Russia1512202331223324124062025Copyright © 2023,2023keywords: cervical screeningHPV testvalidation.ключевые слова: цервикальный скринингВПЧ тестированиевалидация ВПЧ-тестов.1.American Cancer Society. Mission HPV Cancer Free. Режим доступа: http://ancer.org/hpv (дата обращения 06.04.2020).2.World Health Organization. Global Strategy Towards the Elimination of Cervical Cancer as a Public Health Problem. Accessed June 2, 2020. Режим доступа: http://who.int/activities/a-global-strategy-for-elimination-of-cervical-cancer (дата обращения 02.06.2020).3.Arbyn M., Gultekin M., Morice P. European response to the WHO call to eliminate cervical cancer as a public health problem. Int. J. Cancer. 2020;(1):28—34.4.Cостояние онкологической помощи населению России. Под ред. А. Д. Каприна, В. В. Старинского, А. О. Шахзадовой. М.; 2020. 239 с.5.Кононова И. Н., Башмакова Н. В., Берзин С. А., Борисевич Г. А., Мартемьянова В. В., Кузнецова Ю. Н., Шмакова Н. А. Эпидемиология папилломавирусной инфекции и сопряженных с ней онкозаболеваний репродуктивных органов в Свердловской области. Акушерство и гинекология. 2020;(1):74—80.6.Димитриади Т. А., Кит О. И., Бурцев Д. В. Скрининг рака шейки матки. Мировой опыт. Ситуация в России. Естественные науки. 2017;4(2):26—32.7.Коннон С. Р., Союнов М. А. Рак шейки матки: профилактика и скрининг. Акушерство и гинекология: новости, мнения, обучение. 2018;6(3):72—82.8.Логинова Е. В., Крецу В. Н., Ахматова А. Н., Погасов А. Г. Проблемы цервикального скрининга. Акушерство и гинекология: новости, мнения, обучение. 2018;6(3):51—4. doi: 10.24411/2303-9698-2018-139089.Steinberg J., Caruana M. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020—99: a modelling study. Lancet Oncol. 2019;20:394—407.10.Tota J. E., Bentley J., Blake J. Introduction of molecular HPV testing as the primary technology in cervical cancer screening: acting on evidence to change the current paradigm. Prevent. Med. 2017;98:5—14.11.Flanagan M. B. Primary high-risk human papillomavirus testing for cervical cancer screening in the United States: is it Journal of Oncology 11 time? Arch. Pathol. Lab. Med. 2018;142(6):688—92.12.Austin R. M. Can HPV primary screening reduce cervical cancer incidence and mortality? SCAN. 2014;25(1):7—8.13.Karsa L. European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. Papillomavirus Res. 2015;340(3):22—31. doi: 10.1016/j.pvr.2015.06.00614.Горяева А. Э., Петров Ю. А. Скрининг рака шейки матки. Международный журнал прикладных и фундаментальных исследований. 2018;(4):171—5.15.Cheung L. C., Egemen D., Chen X. ASCCP risk-based management consensus guidelines: methods for risk estimation, recommended management, and validation. J. Lower Genital Tract Dis. 2020;24(2):90—101.16.Wright T. C., Stoler M. Н., Behrens С. М. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gyn. Oncol. 2015;136(2):189—97.17.Karsa L., Arbyn M., Vuyst H. “Executive summary” in European Guidelines for Quality Assurance in Cervical Cancer Screening, Office for Official Publications of the European Union. 2nd ed. Luxembourg; 2015. 12 p.18.Koliopoulos G., Nyaga V. N., Santesso N. Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst. Rev. 2017;8(8):85—7.19.Chrysostomou D., Stylianou A., Constantinidou L. Cervical cancer screening programs in Europe: the transition towards HPV vaccination and populationbased HPV testing. Viruses. 2018;10(12):729—40.20.Rossi P. G., Baldacchini F., Ronco G. Possible effects on socio-economic inequalities of introducing HPV testing as primary test in cervical cancer screening programs. Front. Oncol. 2014;4(20):527—32.21.National Cancer Institute (NCI). HPV and Cancer. Updated February 19, 2015. Режим доступа: https://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hpv-fact-sheet (дата обращения 11.12.2018).22.Туранова О. В., Белокриницкая Т. Е., Фролова Н. И. и др. Современный подход к первичному цервикальному скринингу (обзор литературы). Acta Biomedica Scientifica. 2018;3(3):47—53.23.Bonde J. H., Sandri M. T., Gary D. S., Andrews G. C. Clinical utility of human papillomavirus genotyping in cervical cancer screening: a systematic review. J. Lower Genital Tract Dis. 2020;24(1):1—13.24.National Institute for Public Health and the Environment. 2018. Cervical cancer screening programme. Режим доступа: https://www.rivm.nl/en/Topics/C/Cervical_cancer_screening_programme25.Кононова И. Н., Башмакова Н. В., Шмакова Н. А., Вайнберг Э. И., Ребрикова Л. Н., Мартемьянова В. В., Коротаева Н. В., Бейкин Я. В. Оценка дискордантных результатов цитологического исследования цервикального эпителия, обработанного традиционным методом и методом жидкостной цитологии. Акушерство и гинекология. 2020;(4):86—92.26.Шмакова Н. А., Чистякова Г. Н., Кононова И. Н., Ремизова И. И. Особенности генотипирования папилломавирусной инфекции у пациенток с цервикальными интраэпителиальными неоплазиями. Ульяновский медико-биологический журнал. 2020;(3):104—11.27.Wright T., Zhang G., Behrens C. M. Screening with Prejudice; how knowledge of patients HPV status impacts the performance of cervical cytology in the ATHENA trial. Abstracts 15 Wold Congress for Cervical Pathology and Colposcopy. 2014. P. 56—7.28.HPV tests validated for screening. Italian group for screening of cervical cancer GISCI (March 2020). Режим доступа: https://www.gisci.it/documenti/documenti_gisci/Rapporto_n5_Test_HPV_Validati.pdf29.Ronco G., Franceschi S. Cervical Cancer Screening: The Transformational Role of Routine Human Papillomavirus Testing. Ann. Intern. Med. 2018;168:75—6.30.Von Karsa L., Arbyn M., De Vuyst H. European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. Papillomavirus Res. 2015. doi: 10.1016/j.pvr.2015.06.00631.Karlsen F., Keegan H., McInerney J. Comparison of HPV detection technologies: Hybrid capture 2, PreTect HPV-Proofer and analysis of HPV DNA viral load in HPV16, HPV18 and HPV33 E6/E7 mRNA positive specimens. J. Virol. Methods. 2009;155(1):61—6.32.Cuzick J. Comparing the performance of six human papillomavirus tests in a screening population. BJC. 2013;108(9):908—13.33.Zhou H., Mody R., Luna E. Sensitivity of the cobas HPV Test in detecting biopsy-confirmed CIN2/3 cervical lesions: analysis of 33,857 cases with cytology and HPV cotesting contesting. J. Am. Soc. Cytopathol. 2014;3(5):39—56.34.Meijer M. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women of 30 years and older. Int. J. Cancer. 2009;124(3):516—20.35.Кононова И. Н., Башмакова Н. В., Гаева О. Э., Крестьянинова Т. В. Региональный опыт вирусологического цервикального скрининга в Свердловской области. Акушерство и гинекология. 2019;(8):84—9.36.Минниахметов И. Р., Забелин М. В., Ольков И. Г., Хусаинова Р. И. Пилотный проект по скринингу рака шейки матки с применением ВПЧ-тестирования. Вопросы онкологии. 2020;66(6):618—24.37.Stoler M. H., Austin R. M., Zhao C. Point-Counterpoint: Cervical Cancer Screening Should Be Done by Primary Human Papillomavirus Testing with Genotyping and Reflex Cytology for Women over the Age of 25 Years. J. Clin. Mycrobiol. 2015;53(9):49—55.38.Saville V. Clinical validation of the cobas HPV test on the cobas 6800 system for cervical screening. J. Clin. Microbiol. 2019 Jan 30;57(2):e01239—18. doi: 10.1128/JCM.01239-1839.Wright T. C., Stoler M. H., Behrens C. M., Sharma A., Zhang G., Wright T. L. Primary cervical screening with human papillomavirus: End of study results from the ATHENA study using HPV as the first-line screening test. Gynecol. Oncol. 2015;136(2):189—97. doi: 10.1016/j.ygyno.2014.11.07640.Godoy L., Guimaraes Y., Dias T. High-Risk HPV Types analysis using next generation sequence (NGS) and Cobas in European and Latin women with negative and positive cytology. Abstract IPVC. 2021:104—5.41.Instructions for using the kit Abbott Real Time High Risk HPV Режим доступа: https://www.azernews.az/nation/147858.html42.Heselink A. T., Mejer M. Clinical Validation of the Abbot RealTime High Risk HPV Assay According to the Guidelines for Human Papillomavirus DNA Test Requirements for cervical Screening. JCM. 2013;61(9):2109—20.43.Fuljik M. Comparison of the Clinical and Analytical Performance of the Abbot RealTime High Risk HPV Test to the Performance of Hybrid Capture 2 in Population-Based Cervical Cancer Screening. JCM. 2011;49(5):1721—9.44.Fuljik M. Three-year longitudinal data on the clinical performance of the Abbot RealTime High Risk HPV Test in a cervical cancer screening setting. JVC. 2016;76:915—29.45.Latsuzbaia A., Vanden Broeck D., Van Keer S. Performance of partial genotyping assays on vaginal self-samples vs cervical samples: Abbot RealTime High Risk HPV Assay and BD Onclarity HPV Assay. Oral Abstract EUROGIN. 2021.46.Holtzer-Goor K. M., Brouwer E., Veen N., Dijk S. A. Primary HR HPV population screening for cervical cancer in the Netherlands. 2018.47.Repesa A., Levestad A., Christiansen I. K. Validation and characterization of integration sites in HPV 31,33 and 45 positive cervical samples. Abstract IPVC. 2021:133—42.48.Latsuzbaia A., Keer S., Vanden Broeck D., Sutter P., Donders G., Doyen J., Tjalma W., Weyers S., Vorsters A., Arbyn M. Clinical performance of ALINITY m HR HPV Assay on self-collected vaginal and first-void urine samples within valhudes framework. Abstract IPVC. 2021:162—3.49.Cornall A., Poljak M., Garland S. HPV genotype-specific concordance between EuroArray HPV, Anyplex II HPV 28 and Linear Array HPV Genotyping Test in Australian Cervical Samples. Papillomavirus Res. 2017;4:79—84.50.Han В., Fu Y., Li X., Li L., Zhu X., Zhang C., Gao Y., Xie X., Hua B., Wang X. Hybrid capture HPV test with hpv16/18 genotyping provides a new Way for cervical cancer screening: a 3-year follow-up trial. Abstract IPVC. 2021:51.51.Arbyn M., Latsuzbaia A. Meta-analysis of the clinical accuracy of HR HPV DNA Testing on urine versus on clinician — taken cervical samples. Abstract IPVC. 2021:57—8.